Back to results
US 5,310,732 AGranted
2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
AssigneeThe Scripps Research Institute
InventorsDennis A. Carson, Carlos J. Carrera
Life of this patent
Estimating the term…
Abstract
Novel adenine derivatives whose structures are represented by Formula I, are disclosed, as are methods of using those compounds and others of Formula II to treat monocyte-mediated disorders such as rheumatoid arthritis and multiple sclerosis.
Claims5
A method of treating rheumatoid arthritis in a human comprising:
- administering to said human a composition containing a therapeutically effective dose of a substituted adenine derivative that is a 2-halo-2'-deoxyadenosine as an active ingredient dissolved or dispersed in a physiologically tolerable carrier, said substituted adenine derivative being administered in an amount sufficient to decrease the level of monocytes in the blood of said human by at least about 50 percent during the course of said treatment.
A method of treating rheumatoid arthritis in a human comprising:
- administering to said human a composition containing a therapeutically effective dose of a substituted adenine derivative that is 2-chloro-2'-deoxyadenosine as an active ingredient dissolved or dispersed in a physiologically tolerable carrier, said substituted adenine derivative being repeatedly administered in an amount sufficient to decrease the level of monocytes in the blood of said human by at least about 50% during the course of said treatment.
Dependencies are inferred from the claim text.